Spinal Muscular Atrophy Clinical Trial Pipeline: Emerging Therapies and Key Developments Shaping the Treatment Landscape | DelveInsight

(Albany, US) On November 02, 2026, DelveInsight’s “Spinal Muscular Atrophy Pipeline Insight 2026” report provides comprehensive insights about 19+ companies and 20+ pipeline drugs in the Spinal Muscular Atrophy pipeline landscape. It covers the Spinal Muscular Atrophy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Spinal Muscular Atrophy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Spinal Muscular Atrophy Research @ https://www.delveinsight.com/sample-request/spinal-muscular-atrophy-sma-pipeline-insight

Key Takeaways from the Spinal Muscular Atrophy Pipeline Report

• On October 29, 2026 – Novartis updated its Phase IV STREAM study evaluating the real-world safety and effectiveness of intrathecal onasemnogene abeparvovec (ITVISMA) in patients with SMA in the United States. The study’s recruitment sites expanded from one to six, supporting further evaluation of this gene therapy in routine clinical practice
• On October 22, 2026 – Novartis updated its clinical study of intrathecal onasemnogene abeparvovec (Zolgensma) in patients with SMA in Japan. The non-interventional study is recruiting and aims to assess the treatment’s safety and effectiveness in routine clinical practice, with a planned enrollment of 80 participants.
• On October 14, 2026, Biogen reported an update to its Phase III study evaluating salanersen (BIIB115) in infants with genetically diagnosed SMA who had previously received onasemnogene abeparvovec gene therapy. The study is designed to assess the safety, tolerability, and potential efficacy of adding salanersen following gene therapy. The registry reported an October 14 update, with the study’s actual start date listed as October 30, 2026.
• On October 8, 2026 – Scholar Rock announced the resubmission of its Marketing Authorisation Application (MAA) for apitegromab (ISEMBYLD) to the European Medicines Agency (EMA) for the treatment of children and adults with spinal muscular atrophy. The revised application includes an alternative fill-finish manufacturing facility following regulatory feedback. The company anticipates a CHMP opinion in the first half of 2027.
• DelveInsight’s Spinal Muscular Atrophy pipeline report depicts a robust space with 19+ active players working to develop 20+ pipeline therapies for Spinal Muscular Atrophy treatment.
• The leading Spinal Muscular Atrophy Companies include Ionis Pharmaceuticals, Scholar Rock, Biogen, Astellas Pharma, Alcyone Therapeutics, AndroScience Corporation, Hanugen Theraputics, Voyager Therapeutics, Hoffmann-La Roche, Catalyst Pharmaceuticals, NMD Pharma, Biohaven Pharmaceuticals, CANbridge Pharmaceuticals Inc., Aurimed Pharma, Exicure, Amylon Therapeutics, Amniotics and others.
• Promising Spinal Muscular Atrophy Pipeline Therapies such as OAV101, Risdiplam, Nusinersen, Amifampridine Phosphate, vesemnogene lantuparvovec, Olesoxime, NMD670 and others.

Stay informed about the cutting-edge advancements in Spinal Muscular Atrophy treatments @ Spinal Muscular Atrophy Clinical Trials Assessment

The Spinal Muscular Atrophy Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Spinal Muscular Atrophy Pipeline Report also highlights the unmet needs with respect to the Spinal Muscular Atrophy.

Spinal Muscular Atrophy Overview

Spinal muscular atrophy (SMA) is a rare inherited neuromuscular disorder characterized by progressive degeneration of the anterior horn cells (lower motor neurons) in the spinal cord, resulting in symmetrical proximal muscle weakness, muscle atrophy, and hypotonia. The disease is primarily caused by homozygous deletion or mutation of the survival motor neuron 1 (SMN1) gene on chromosome 5q13, which accounts for approximately 95% of cases. SMA exhibits a broad clinical spectrum, ranging from severe prenatal or infantile-onset forms associated with early mortality to milder adult-onset forms with relatively preserved life expectancy. It is one of the leading genetic causes of infant mortality and follows an autosomal recessive inheritance pattern.

Spinal Muscular Atrophy Emerging Drugs Profile

• Salanersen: Biogen

Salanersen is a novel, intrathecally administered antisense oligonucleotide (ASO) in development for SMA. Salanersen is designed to correct splicing of SMN2 pre-mRNA to increase production of SMN protein. It has a new chemistry that leads to high potency, enabling the potential for high efficacy with once-yearly dosing. In June 2026, Biogen Inc announced that the US Food and Drug Administration (FDA) has granted salanersen Breakthrough Therapy Designation for the treatment of spinal muscular atrophy (SMA). Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Spinal Muscular Atrophy.

• GC101: GeneCradle Therapeutics

GC101 is an adeno-associated virus (AAV)-based gene therapy designed to deliver a functional SMN1 (survival motor neuron 1) gene expression cassette to motor neurons using a recombinant AAV vector. Following intrathecal, intravenous, or intraventricular administration, the vector efficiently transduces the central nervous system, enabling sustained expression of the SMN protein in neurons. By restoring SMN protein levels, GC101 aims to improve motor neuron survival and function, thereby addressing the underlying genetic cause of SMA rather than only alleviating symptoms. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Spinal Muscular Atrophy.

• GB221: Gemma Biotherapeutics

GB221 is an investigational, next?generation gene therapy for SMA1 developed to express SMN1 in motor neurons. The absence of functional SMN1 protein in motor neurons is the underlying cause of SMA. GB221 is a one-time gene therapy that consists of an adeno?associated virus (AAV) human isolate, AAVhu68, encasing a functional copy of a codon?optimized SMN1 gene in a modified transgene expression cassette designed to reduce overexpression and sensory neurotoxicity. It is delivered directly to the cerebrospinal fluid (CSF) via intra-cisterna magna (ICM) injection. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Spinal Muscular Atrophy.

ARV-027: Arvinas

ARV-027 is an investigational oral, peripherally restricted PROTAC degrader designed to selectively target and eliminate toxic polyglutamine-expanded androgen receptor (polyQ-AR) in skeletal muscle. PolyQ-AR is the root cause of motor dysfunction in spinal bulbar muscular atrophy (SBMA) or Kennedy’s disease due to the toxic gain of function imparted by the polyQ expansion on the AR. PolyQ-AR misfolds and aggregates in a ligand-dependent manner, disrupts normal transcription, and impairs muscle and mitochondrial function, ultimately driving progressive neuromuscular degeneration. . Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Spinal bulbar muscular atrophy.

Learn more about Spinal Muscular Atrophy Drugs opportunities in our groundbreaking research @ Spinal Muscular Atrophy Unmet Needs

The Spinal Muscular Atrophy Pipeline Report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Spinal Muscular Atrophy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Spinal Muscular Atrophy Treatment.
• Spinal Muscular Atrophy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Spinal Muscular Atrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Spinal Muscular Atrophy market.

Spinal Muscular Atrophy Companies

Ionis Pharmaceuticals, Scholar Rock, Biogen, Astellas Pharma, Alcyone Therapeutics, AndroScience Corporation, Hanugen Theraputics, Voyager Therapeutics, Hoffmann-La Roche, Catalyst Pharmaceuticals, NMD Pharma, Biohaven Pharmaceuticals, CANbridge Pharmaceuticals Inc., Aurimed Pharma, Exicure, Amylon Therapeutics, Amniotics and others.

Spinal muscular atrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Spinal Muscular Atrophy Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Discover the latest advancements in Spinal Muscular Atrophy treatment by visiting our website @ Spinal Muscular Atrophy Market Drivers and Barriers, and Future Perspectives

Scope of the Spinal Muscular Atrophy Pipeline Report

• Coverage- Global
• Spinal Muscular Atrophy Companies- Ionis Pharmaceuticals, Scholar Rock, Biogen, Astellas Pharma, Alcyone Therapeutics, AndroScience Corporation, Hanugen Theraputics, Voyager Therapeutics, Hoffmann-La Roche, Catalyst Pharmaceuticals, NMD Pharma, Biohaven Pharmaceuticals, CANbridge Pharmaceuticals Inc., Aurimed Pharma, Exicure, Amylon Therapeutics, Amniotics and others.
• Spinal Muscular Atrophy Pipeline Therapies- OAV101, Risdiplam, Nusinersen, Amifampridine Phosphate, vesemnogene lantuparvovec, Olesoxime, NMD670 and others.
• Spinal Muscular Atrophy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Spinal Muscular Atrophy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Read the full details of Spinal Muscular Atrophy Pipeline on our website @ Spinal Muscular Atrophy Emerging Drugs and Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Spinal muscular atrophy: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Spinal muscular atrophy – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Apitegromab: Scholar Rock
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Branaplam: Novartis
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. ACTX 401: Alcyone Therapeutics
15. Drug profiles in the detailed report….
16. Inactive Products
17. Spinal muscular atrophy Unmet Needs
18. Spinal muscular atrophy Market Drivers and Barriers
19. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/spinal-muscular-atrophy-sma-pipeline-insight